On August 21, Merck rose 3.04% in regular trading, trading at $153.58/share, with turnover of $411 million, extending its recent strong performance following a landmark clinical milestone.

The continued upward momentum stems from Merck and Moderna's joint announcement on August 19 that their Phase III clinical trial INTerpath-001 for the personalized mRNA cancer vaccine intismeran autogene combined with Keytruda met its primary endpoint of recurrence-free survival and key secondary endpoint of distant metastasis-free survival in patients with completely resected stage IIB-IV melanoma. The combination demonstrated statistically significant and clinically meaningful improvements compared with Keytruda alone, with safety profiles consistent with previously reported results. This marks the world's first personalized mRNA cancer vaccine to achieve positive Phase III results. Both companies have indicated they will engage with regulators regarding filing submissions.

The stock surged over 12% on August 19 — its best single-day gain since 2009 — and continues to attract buying interest. Royal Bank of Canada noted that Merck's valuation is now at historical highs, with further upside requiring pipeline outperformance beyond expectations.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)